257 related articles for article (PubMed ID: 32141939)
21. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
[TBL] [Abstract][Full Text] [Related]
22. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
[TBL] [Abstract][Full Text] [Related]
23. [Development and treatment of localized/systemic BCGitis : Retrospective studies in direct comparison to mitomycin C].
Böhm WU; Koch R; Wenzel S; Wirth MP; Toma M
Urologe A; 2018 May; 57(5):568-576. PubMed ID: 29500474
[TBL] [Abstract][Full Text] [Related]
24. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
25. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.
González-Padilla DA; González-Díaz A; Guerrero-Ramos F; Rodríguez-Serrano A; García-Jarabo E; Corona-laPuerta M; Rodríguez-Antolín A; Villacampa-Aubá F
Urol Oncol; 2021 Jan; 39(1):76.e9-76.e14. PubMed ID: 32753359
[TBL] [Abstract][Full Text] [Related]
26. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
27. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
28. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
[TBL] [Abstract][Full Text] [Related]
29. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Arends TJ; van der Heijden AG; Witjes JA
J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
[TBL] [Abstract][Full Text] [Related]
30. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.
Veeratterapillay R; Heer R; Johnson MI; Persad R; Bach C
Curr Urol Rep; 2016 Sep; 17(9):68. PubMed ID: 27492610
[TBL] [Abstract][Full Text] [Related]
31. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
32. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.
Abou Chakra M; Shore ND; Dillon R; O'Donnell MA
Urol Pract; 2024 Jan; 11(1):97-107. PubMed ID: 37903746
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
Lan Y; Liu D; Lin M
Neoplasma; 2016; 63(6):967-976. PubMed ID: 27596297
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
36. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
37. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
Böhle A; Jocham D; Bock PR
J Urol; 2003 Jan; 169(1):90-5. PubMed ID: 12478111
[TBL] [Abstract][Full Text] [Related]
38. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
39. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
40. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
